Rational design and synthesis of ansa-adenosines as potential antitumor agents. 2009

Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
Faculty of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.

Synthesis of benzoquinone ansa-adenosines, which are rationally designed as Hsp90 inhibitors by extracting and fusing a natural substrate, ATP, and a natural product, geldanamycin, was described. This simpler scaffold design provides practical synthesis of a set of analogs and demonstrates synthetic innovation.

UI MeSH Term Description Entries
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000255 Adenosine Triphosphate An adenine nucleotide containing three phosphate groups esterified to the sugar moiety. In addition to its crucial roles in metabolism adenosine triphosphate is a neurotransmitter. ATP,Adenosine Triphosphate, Calcium Salt,Adenosine Triphosphate, Chromium Salt,Adenosine Triphosphate, Magnesium Salt,Adenosine Triphosphate, Manganese Salt,Adenylpyrophosphate,CaATP,CrATP,Manganese Adenosine Triphosphate,MgATP,MnATP,ATP-MgCl2,Adenosine Triphosphate, Chromium Ammonium Salt,Adenosine Triphosphate, Magnesium Chloride,Atriphos,Chromium Adenosine Triphosphate,Cr(H2O)4 ATP,Magnesium Adenosine Triphosphate,Striadyne,ATP MgCl2
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D016227 Benzoquinones Benzene rings which contain two ketone moieties in any position. They can be substituted in any position except at the ketone groups. 1,2-Benzoquinones,1,4-Benzoquinones,Benzodiones,2,5-Cyclohexadiene-1,4-Diones,o-Benzoquinones,p-Benzoquinones
D047029 Lactams, Macrocyclic LACTAM-forming compounds with a ring size of approximately 1-3 dozen atoms. Ansamycins,Macrocyclic Lactams
D018841 HSP90 Heat-Shock Proteins A class of MOLECULAR CHAPERONES whose members act in the mechanism of SIGNAL TRANSDUCTION by STEROID RECEPTORS. Heat-Shock Proteins 90,HSP90 Heat Shock Proteins,Heat Shock Proteins 90,Heat-Shock Proteins, HSP90

Related Publications

Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
July 2010, Bioorganic & medicinal chemistry letters,
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
August 2002, Archives of pharmacal research,
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
December 1977, The Japanese journal of antibiotics,
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
July 2011, Medicinal chemistry (Shariqah (United Arab Emirates)),
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
October 2014, Bioorganic & medicinal chemistry letters,
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
January 2018, Medicinal chemistry (Shariqah (United Arab Emirates)),
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
December 2021, Acta pharmaceutica (Zagreb, Croatia),
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
September 2019, European journal of medicinal chemistry,
Kazuhiro Muranaka, and Satoshi Ichikawa, and Akira Matsuda
December 2019, Journal of inorganic biochemistry,
Copied contents to your clipboard!